Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eptifibatide

FDA-approved product (injectable, injection), marketed as Eptifibatide, Integrilin.

Registered studies
35
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Eptifibatide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Acute myocardial infarction
  • Intermediate coronary syndrome
  • Myocardial infarction
  • Recurrent thrombophlebitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
Platelet Aggregation Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

35registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eptifibatide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eptifibatide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

    NCT00111566 · start 2004-12

    Registered record
    Registry ID
    NCT00111566
    Conditions
    Coronary Artery Disease; Myocardial Infarction
    Interventions
    eptifibatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-12
    Completion
    2007-08
    Enrolment
    624

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Myocardial Infarction
    Interventioneptifibatide
    PhasePhase 4
    Registry statusCompleted

  • EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)

    NCT00089895 · start 2004-11-01

    Registered record
    Registry ID
    NCT00089895
    Conditions
    Myocardial Ischemia; Acute Coronary Syndrome
    Interventions
    Eptifibatide (Integrilin); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-11-01
    Completion
    2008-11-01
    Enrolment
    9,406

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Ischemia; Acute Coronary Syndrome
    InterventionEptifibatide (Integrilin); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial

    NCT00250991 · start 2003-07

    Registered record
    Registry ID
    NCT00250991
    Conditions
    Stroke
    Interventions
    activase; integrilin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2003-07
    Completion
    2007-07
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke
    Interventionactivase; integrilin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

    NCT00061373 · start 2003-05

    Registered record
    Registry ID
    NCT00061373
    Conditions
    Ischemic Stroke
    Interventions
    Aspirin; tinzaparin sodium; eptifibatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-05
    Completion
    2011-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke
    InterventionAspirin; tinzaparin sodium; eptifibatide
    PhasePhase 2
    Registry statusCompleted

  • PROTECT-TIMI 30 Trial

    NCT00250471 · start 2003-05

    Registered record
    Registry ID
    NCT00250471
    Conditions
    Unstable Angina
    Interventions
    Percutaneous Coronary Intervention (PCI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-05
    Completion
    2004-09
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnstable Angina
    InterventionPercutaneous Coronary Intervention (PCI)
    PhasePhase 3
    Registry statusCompleted